Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1995 May;63(5):1637–1644. doi: 10.1128/iai.63.5.1637-1644.1995

Direct anticryptococcal activity of lymphocytes from Cryptococcus neoformans-immunized mice.

S M Muth 1, J W Murphy 1
PMCID: PMC173203  PMID: 7729867

Abstract

Assessment of the direct anticryptococcal activity of murine lymphocytes from both Cryptococcus neoformans-immunized and control mice was the focus of this investigation. We demonstrate that at a 2:1 effector cell-to-cryptococcal target cell ratio, effector cell populations comprised of alpha beta T-cell receptor-positive T lymphocytes (98 to 99% CD3+) from C. neoformans-immunized mice inhibited the growth of cryptococcal cells better than similar populations of lymphocytes from nonimmunized control mice. Almost immediately after mixing of cryptococci with the effector cells, C. neoformans-lymphocyte conjugates were observed. The percentage of conjugates increased over the first 30 min of incubation and then remained constant over the next 1.5 h. T-lymphocyte-enriched populations from C. neoformans-immunized mice formed significantly greater percentages of conjugates with cryptococci than control T lymphocytes at each time period that assessment was made. For growth inhibition to occur, direct contact between the effector and target cells was necessary, as evidenced by abrogation of cryptococcal growth inhibition when lymphocyte and cryptococcal cell populations were separated by a porous membrane during the growth inhibition assay. Vital staining of cryptococci after incubation with the T-cell-enriched populations showed that the T lymphocytes killed the cryptococcal cells.

Full Text

The Full Text of this article is available as a PDF (238.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson D. M., Dykstra M. A. Resistance to challenge and macrophage activity in mice previously vaccinated with formalin-killed Cryptococcus neoformans. Mycopathologia. 1984 Jun 30;86(3):169–177. doi: 10.1007/BF00441128. [DOI] [PubMed] [Google Scholar]
  2. Buchanan K. L., Murphy J. W. Characterization of cellular infiltrates and cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response. Infect Immun. 1993 Jul;61(7):2854–2865. doi: 10.1128/iai.61.7.2854-2865.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chuck S. L., Sande M. A. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med. 1989 Sep 21;321(12):794–799. doi: 10.1056/NEJM198909213211205. [DOI] [PubMed] [Google Scholar]
  4. Edson R. S., Fernandez-Guerrero M. L., Roberts G. D., Van Scoy R. E. Clinical and laboratory features of cryptococcosis. A five-year experience. Minn Med. 1987 Jun;70(6):337–342. [PubMed] [Google Scholar]
  5. Elloso M. M., van der Heyde H. C., vande Waa J. A., Manning D. D., Weidanz W. P. Inhibition of Plasmodium falciparum in vitro by human gamma delta T cells. J Immunol. 1994 Aug 1;153(3):1187–1194. [PubMed] [Google Scholar]
  6. Fung P. Y., Murphy J. W. In vitro interactions of immune lymphocytes and Cryptococcus neoformans. Infect Immun. 1982 Jun;36(3):1128–1138. doi: 10.1128/iai.36.3.1128-1138.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gentry L. O., Remington J. S. Resistance against Cryptococcus conferred by intracellular bacteria and protozoa. J Infect Dis. 1971 Jan;123(1):22–31. doi: 10.1093/infdis/123.1.22. [DOI] [PubMed] [Google Scholar]
  8. Graybill J. R. Future directions of antifungal chemotherapy. Clin Infect Dis. 1992 Mar;14 (Suppl 1):S170–S181. doi: 10.1093/clinids/14.supplement_1.s170. [DOI] [PubMed] [Google Scholar]
  9. Heenan P. J., Dawkins R. L. Cryptococcosis with multiple squamous cell tumors associated with a T-cell defect. Cancer. 1981 Jan 15;47(2):291–295. doi: 10.1002/1097-0142(19810115)47:2<291::aid-cncr2820470214>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  10. Hidore M. R., Mislan T. W., Murphy J. W. Responses of murine natural killer cells to binding of the fungal target Cryptococcus neoformans. Infect Immun. 1991 Apr;59(4):1489–1499. doi: 10.1128/iai.59.4.1489-1499.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hidore M. R., Murphy J. W. Murine natural killer cell interactions with a fungal target, Cryptococcus neoformans. Infect Immun. 1989 Jul;57(7):1990–1997. doi: 10.1128/iai.57.7.1990-1997.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hidore M. R., Nabavi N., Reynolds C. W., Henkart P. A., Murphy J. W. Cytoplasmic components of natural killer cells limit the growth of Cryptococcus neoformans. J Leukoc Biol. 1990 Jul;48(1):15–26. doi: 10.1002/jlb.48.1.15. [DOI] [PubMed] [Google Scholar]
  13. Hidore M. R., Nabavi N., Sonleitner F., Murphy J. W. Murine natural killer cells are fungicidal to Cryptococcus neoformans. Infect Immun. 1991 May;59(5):1747–1754. doi: 10.1128/iai.59.5.1747-1754.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hill J. O., Harmsen A. G. Intrapulmonary growth and dissemination of an avirulent strain of Cryptococcus neoformans in mice depleted of CD4+ or CD8+ T cells. J Exp Med. 1991 Mar 1;173(3):755–758. doi: 10.1084/jem.173.3.755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Huffnagle G. B., Yates J. L., Lipscomb M. F. Immunity to a pulmonary Cryptococcus neoformans infection requires both CD4+ and CD8+ T cells. J Exp Med. 1991 Apr 1;173(4):793–800. doi: 10.1084/jem.173.4.793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Julius M. H., Simpson E., Herzenberg L. A. A rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur J Immunol. 1973 Oct;3(10):645–649. doi: 10.1002/eji.1830031011. [DOI] [PubMed] [Google Scholar]
  17. Khan I. A., Smith K. A., Kasper L. H. Induction of antigen-specific human cytotoxic T cells by Toxoplasma gondii. J Clin Invest. 1990 Jun;85(6):1879–1886. doi: 10.1172/JCI114649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Khan I. A., Smith K. A., Kasper L. H. Induction of antigen-specific parasiticidal cytotoxic T cell splenocytes by a major membrane protein (P30) of Toxoplasma gondii. J Immunol. 1988 Nov 15;141(10):3600–3605. [PubMed] [Google Scholar]
  19. Knobloch C., Dennert G. Asialo-GM1-positive T killer cells are generated in F1 mice injected with parental spleen cells. J Immunol. 1988 Feb 1;140(3):744–749. [PubMed] [Google Scholar]
  20. Kovacs J. A., Kovacs A. A., Polis M., Wright W. C., Gill V. J., Tuazon C. U., Gelmann E. P., Lane H. C., Longfield R., Overturf G. Cryptococcosis in the acquired immunodeficiency syndrome. Ann Intern Med. 1985 Oct;103(4):533–538. doi: 10.7326/0003-4819-103-4-533. [DOI] [PubMed] [Google Scholar]
  21. Kupfer A., Singer S. J. Cell biology of cytotoxic and helper T cell functions: immunofluorescence microscopic studies of single cells and cell couples. Annu Rev Immunol. 1989;7:309–337. doi: 10.1146/annurev.iy.07.040189.001521. [DOI] [PubMed] [Google Scholar]
  22. Levitz S. M., Dupont M. P. Phenotypic and functional characterization of human lymphocytes activated by interleukin-2 to directly inhibit growth of Cryptococcus neoformans in vitro. J Clin Invest. 1993 Apr;91(4):1490–1498. doi: 10.1172/JCI116354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Levitz S. M., Dupont M. P., Smail E. H. Direct activity of human T lymphocytes and natural killer cells against Cryptococcus neoformans. Infect Immun. 1994 Jan;62(1):194–202. doi: 10.1128/iai.62.1.194-202.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Levitz S. M., Farrell T. P., Maziarz R. T. Killing of Cryptococcus neoformans by human peripheral blood mononuclear cells stimulated in culture. J Infect Dis. 1991 May;163(5):1108–1113. doi: 10.1093/infdis/163.5.1108. [DOI] [PubMed] [Google Scholar]
  25. Lim T. S., Murphy J. W. Transfer of immunity to cryptococcosis by T-enriched splenic lymphocytes from Cryptococcus neoformans-sensitized mice. Infect Immun. 1980 Oct;30(1):5–11. doi: 10.1128/iai.30.1.5-11.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Mackaness G. B., Blanden R. V. Cellular immunity. Prog Allergy. 1967;11:89–140. [PubMed] [Google Scholar]
  27. Morrow J. D. Fluconazole: a new triazole antifungal agent. Am J Med Sci. 1991 Aug;302(2):129–132. doi: 10.1097/00000441-199108000-00012. [DOI] [PubMed] [Google Scholar]
  28. Murphy J. W., Cozad G. C. Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect Immun. 1972 Jun;5(6):896–901. doi: 10.1128/iai.5.6.896-901.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Murphy J. W., Hidore M. R., Nabavi N. Binding interactions of murine natural killer cells with the fungal target Cryptococcus neoformans. Infect Immun. 1991 Apr;59(4):1476–1488. doi: 10.1128/iai.59.4.1476-1488.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Murphy J. W., Hidore M. R., Wong S. C. Direct interactions of human lymphocytes with the yeast-like organism, Cryptococcus neoformans. J Clin Invest. 1993 Apr;91(4):1553–1566. doi: 10.1172/JCI116361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Murphy J. W., McDaniel D. O. In vitro reactivity of natural killer (NK) cells against Cryptococcus neoformans. J Immunol. 1982 Apr;128(4):1577–1583. [PubMed] [Google Scholar]
  32. Muth S. M., Murphy J. W. Effects of immunization with Cryptococcus neoformans cells or cryptococcal culture filtrate antigen on direct anticryptococcal activities of murine T lymphocytes. Infect Immun. 1995 May;63(5):1645–1651. doi: 10.1128/iai.63.5.1645-1651.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Nabavi N., Murphy J. W. In vitro binding of natural killer cells to Cryptococcus neoformans targets. Infect Immun. 1985 Oct;50(1):50–57. doi: 10.1128/iai.50.1.50-57.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Parker S. E., Sun Y. H., Sears D. W. Differential expression of the ASGM1 antigen on anti-reovirus and alloreactive cytotoxic T lymphocytes (CTL). J Immunogenet. 1988 Aug;15(4):215–226. doi: 10.1111/j.1744-313x.1988.tb00424.x. [DOI] [PubMed] [Google Scholar]
  35. Salata R. A., Martinez-Palomo A., Murray H. W., Conales L., Trevino N., Segovia E., Murphy C. F., Ravdin J. I. Patients treated for amebic liver abscess develop cell-mediated immune responses effective in vitro against Entamoeba histolytica. J Immunol. 1986 Apr 1;136(7):2633–2639. [PubMed] [Google Scholar]
  36. Sugar A. M. Overview: cryptococcosis in the patient with AIDS. Mycopathologia. 1991 Jun;114(3):153–157. doi: 10.1007/BF00437205. [DOI] [PubMed] [Google Scholar]
  37. Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989;47:187–376. doi: 10.1016/S0065-2776(08)60664-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Tschopp J., Nabholz M. Perforin-mediated target cell lysis by cytolytic T lymphocytes. Annu Rev Immunol. 1990;8:279–302. doi: 10.1146/annurev.iy.08.040190.001431. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES